{{Drugbox
| drug_name = 
| IUPAC_name        = ''N''-[2-<nowiki>[[</nowiki>2-[(2''S'')-2-Cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-''a'']pyrimidine-6-carboxamide
| image             = Anagliptin.svg 
| alt               = 
| caption           =

<!-- Clinical data -->
| tradename         = Suiny
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = Approved in Japan
| routes_of_administration = Oral

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         =

<!-- Identifiers -->
| CAS_number        = 739366-20-2
| ATCvet            = 
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 
| DrugBank          =
| ChemSpiderID      = 28492667

<!-- Chemical data -->
| C=19 | H=25 | N=7 | O=2
| molecular_weight  = 383.45 g/mol
| smiles = CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N
| StdInChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
| StdInChIKey= LDXYBEHACFJIEL-HNNXBMFYSA-N
}}

'''Anagliptin''' ([[International Nonproprietary Name|INN]]; trade name '''Suiny''') is a pharmaceutical drug for the treatment of [[type 2 diabetes mellitus]].  It is approved for use in Japan.<ref>{{cite journal|url=http://thomsonreuters.com/business-unit/science/pdf/ls/years_new_drugs_biologics-2012.pdf |doi=10.1358/dot.2013.49.1.1933991 |journal=Drugs of Today |year=2013 |volume=49 |issue=1 |pages=33â€“68 |author1=A.I. Graul |author2=B. Lupone |author3=E. Cruces |author4=M. Stringer |title=2012 in Review - Part I: The Year's New Drugs and Biologics |deadurl=yes |archiveurl=https://web.archive.org/web/20131103135328/http://thomsonreuters.com/business-unit/science/pdf/ls/years_new_drugs_biologics-2012.pdf |archivedate=2013-11-03 }}</ref>  It belongs to the class of anti-diabetic drugs known as [[dipeptidyl peptidase-4 inhibitor]]s or "gliptins".<ref>{{cite journal | doi = 10.1016/j.bmc.2011.09.043 | title = Discovery and pharmacological characterization of N-\2-({2-\(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo\1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor | year = 2011 | last1 = Kato | first1 = Noriyasu | last2 = Oka | first2 = Mitsuru | last3 = Murase | first3 = Takayo | last4 = Yoshida | first4 = Masahiro | last5 = Sakairi | first5 = Masao | last6 = Yamashita | first6 = Satoko | last7 = Yasuda | first7 = Yoshika | last8 = Yoshikawa | first8 = Aya | last9 = Hayashi | first9 = Yuuji | last10 = Makino | first10 = Mitsuhiro | last11 = Takeda | first11 = Motohiro | last12 = Mirensha | first12 = Yakufu | last13 = Kakigami | first13 = Takuji | journal = Bioorganic & Medicinal Chemistry | volume = 19 | issue = 23 | pages = 7221}}</ref>

==References==
{{reflist}}

{{Oral hypoglycemics and insulin_analogs}}

[[Category:Dipeptidyl peptidase-4 inhibitors]]
[[Category:Nitriles]]
[[Category:Pyrazolopyrimidines]]


{{gastrointestinal-drug-stub}}